Key result
AVR linked to ~41% lower 5-year mortality vs surveillance in moderate AS.
Why the study?
Emerging evidence of substantial mortality in untreated moderate AS and improved AVR safety have challenged the traditional risk/benefit paradigm, warranting an appraisal of contemporary data and intervention timing.
Does aortic valve replacement improve outcomes in patients with moderate aortic stenosis compared to clinical surveillance?
Does aortic valve replacement improve outcomes in patients with moderate aortic stenosis compared to clinical surveillance?
Answers are grounded in this paper and cite their sources.
Moderate aortic stenosis is not a benign condition and is associated with significant mortality, prompting re-evaluation of current surveillance guidelines and ongoing trials of early intervention.
Non-rheumatic aortic stenosis (AS) is among the most common valvular diseases in the developed world. Current guidelines support aortic valve replacement (AVR) for severe symptomatic AS, which carries high morbidity and mortality when left untreated. In contrast, moderate AS has historically been thought to be a benign diagnosis for which the potential benefits of AVR are outweighed by the procedural risks. However, emerging data demonstrating the substantial mortality risk in untreated moderate AS and substantial improvements in periprocedural and perioperative mortality with AVR have challenged the traditional risk/benefit paradigm. As such, an appraisal of the contemporary data on morbidity and mortality associated with moderate AS and appropriate timing of valvular intervention in AS is warranted. In this review, we discuss the current understanding of moderate AS, including the epidemiology, current surveillance and management guidelines, clinical outcomes, and future studies.
No takes yet. Share an insight, caveat, or question.
Pankayatselvan et al. (2022) studied moderate aortic stenosis (n=3,315). aortic valve replacement (AVR) vs. no intervention was evaluated on 5-year mortality (HR 0.59, 95% CI 0.35 to 0.98, p=0.04). Aortic valve replacement (AVR) reduced 5-year all-cause mortality to 56% for patients with moderate aortic stenosis, compared to 67% mortality in those who did not receive AVR.
Synapse has enriched 10 related papers. Consider them for comparative context: